Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies

Journal of Immunology

Volumn 184, Issue 8, 2010, Pages 4170-4177

  Porzia, Alessandra ^a   Lanzardo, Stefania ^b   Citti, Arianna ^a   Cavallo, Federica ^b   Forni, Guido ^b   Santoni, Angela ^a   Galandrini, Ricciarda ^a   Paolini, Rossella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATASE AND TENSIN HOMOLOG DELETED FROM CHROMOSOME 10; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CANCER ANTIBODY; ERBB2 PROTEIN, RAT; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; CELL CYCLE PROGRESSION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL STRAIN 3T3; DRUG ANTAGONISM; ELECTROPORATION; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; EXTRACELLULAR SPACE; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3T3 CELLS; ANIMALS; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; ELECTROPORATION; EXTRACELLULAR SPACE; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RATS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; VACCINES, DNA;

EID: 77952785340     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903375     Document Type: Article

References (50)

1. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2: 127-137.
2. Sergina, N. V., and M. M. Moasser. 2007. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol. Med. 13: 527-534.
3. Tzahar, E., H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. J. Ratzkin, and Y. Yarden. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16: 5276-5287.
4. Olayioye, M. A., R. M. Neve, H. A. Lane, and N. E. Hynes. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19: 3159-3167.
5. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
6. Pegram, M. D., R. S. Finn, K. Arzoo, M. Beryt, R. J. Pietras, and D. J. Slamon. 1997. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537-547.
7. Tan, M., J. Yao, and D. Yu. 1997. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57: 1199-1205.
8. Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821.
9. Siegel, P. M., E. D. Ryan, R. D. Cardiff, and W. J. Muller. 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18: 2149-2164.
10. Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak. C. F. Barbas, 3rd, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100: 8933-8938.
11. Cantley, L. C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
12. Maehama, T., and J. E. Dixon. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273: 13375-13378.
13. Stambolic, V., A. Suzuki, J. L. de la Pompa, G. M. Brothers, C. Mirtsos, T. Sasaki, J. Ruland, J. M. Penninger, D. P. Siderovski, and T. W. Mak. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39. (Pubitemid 28458022)
14. Prigent, S. A., and W. J. Gullick. 1994. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13: 2831-2841. (Pubitemid 24191693)
15. Hellyer, N. J., K. Cheng, and J. G. Koland. 1998. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 333: 757-763.
16. Wallasch, C., F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, and A. Ullrich. 1995. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14: 4267-4275.
17. Drebin, J. A., V. C. Link, R. A. Weinberg, and M. I. Greene. 1986. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA 83: 9129-9133.
18. Hudziak, R. M., G. D. Lewis, M. Winget, B. M. Fendly, H. M. Shepard, and A. Ullrich. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9: 1165-1172.
19. Stancovski, I., E. Hurwitz, O. Leitner, A. Ullrich, Y. Yarden, and M. Sela. 1991. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA 88: 8691-8695.
20. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, et al. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14: 737-744.
21. Baselga, J., L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58: 2825-2831. (Pubitemid 28311914)
22. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792.
23. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639-2648.
24. Drebin, J. A., V. C. Link, and M. I. Greene. 1988. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2: 273-277.
25. Harwerth, I. M., W. Wels, J. Schlegel, M. Müller, and N. E. Hynes. 1993. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68: 1140-1145.
26. Hurwitz, E., I. Stancovski, M. Sela, and Y. Yarden. 1995. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA 92: 3353-3357.
27. Klapper, L. N., N. Vaisman, E. Hurwitz, R. Pinkas-Kramarski, Y. Yarden, and M. Sela. 1997. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14: 2099-2109.
28. Spiridon, C. I., M. A. Ghetie, J. Uhr, R. Marches, J. L. Li, G. L. Shen, and E. S. Vitetta. 2002. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8: 1720-1730.
29. Friedman, L. M., A. Rinon, B. Schechter, L. Lyass, S. Lavi, S. S. Bacus, M. Sela, and Y. Yarden. 2005. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 102: 1915-1920.
30. Ben-Kasus, T., B. Schechter, S. Lavi, Y. Yarden, and M. Sela. 2009. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc. Natl. Acad. Sci. USA 106: 3294-3299.
31. Rovero, S., A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P. L. Lollini, et al. 2000. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165: 5133-5142.
32. Curcio, C., E. Di Carlo, R. Clynes, M. J. Smyth, K. Boggio, E. Quaglino, M. Spadaro, M. P. Colombo, A. Amici, P. L. Lollini, et al. 2003. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J. Clin. Invest. 111: 1161-1170.
33. Quaglino, E., S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P. L. Lollini, S. Lanzardo, G. Forni, R. Sanges, et al. 2004. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113: 709-717.
34. Park, J. M., M. Terabe, Y. Sakai, J. Munasinghe, G. Forni, J. C. Morris, and J. A. Berzofsky. 2005. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174: 4228-4236.
35. Qin, Z., G. Richter, T. Schüler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4: 627-630.
36. Street, S. E., N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth. 2007. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res. 67: 5454-5460.
37. Spadaro, M., E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W. Z. Wei, P. Musiani, P. L. Lollini, et al. 2005. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11: 1941-1952.
38. Quaglino, E., M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S. M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, et al. 2004. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 64: 2858-2864. (Pubitemid 38500626)
39. Molfetta, R., F. Gasparrini, G. Peruzzi, L. Vian, M. Piccoli, L. Frati, A. Santoni, and R. Paolini. 2009. Lipid raft-dependent FcepsilonRI ubiquitination regulates receptor endocytosis through the action of ubiquitin binding adaptors. PLoS One 4: e5604.
40. Curcio, C., A. S. Khan, A. Amici, M. Spadaro, E. Quaglino, F. Cavallo, G. Forni, and R. Draghia-Akli. 2008. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther. 15: 108-114.
41. Gullick, W. J., A. C. Bottomley, F. J. Lofts, D. G. Doak, D. Mulvey, R. Newman, M. J. Crumpton, M. J. Sternberg, and I. D. Campbell. 1992. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein. EMBO J. 11: 43-48.
42. Nagata, Y., K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, K. S. Klos, P. Li, B. P. Monia, N. T. Nguyen, et al. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127. (Pubitemid 39485684)
43. Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501.
44. Leslie, N. R., and C. P. Downes. 2004. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382: 1-11.
45. Vogt, P. K., S. Kang, M. A. Elsliger, and M. Gymnopoulos. 2007. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 32: 342-349.
46. Salmena, L., A. Carracedo, and P. P. Pandolfi. 2008. Tenets of PTEN tumor suppression. Cell 133: 403-414.
47. Schade, B., T. Rao, N. Dourdin, R. Lesurf, M. Hallett, R. D. Cardiff, and W. J. Muller. 2009. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J. Biol. Chem. 284: 19018-19026.
48. Yakes, F. M., W. Chinratanalab, C. A. Ritter, W. King, S. Seelig, and C. L. Arteaga. 2002. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62: 4132-4141.
49. Longva, K. E., N. M. Pedersen, C. Haslekås, E. Stang, and I. H. Madshus. 2005. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 116: 359-367.
50. Lee-Hoeflich, S. T., L. Crocker, E. Yao, T. Pham, X. Munroe, K. P. Hoeflich, M. X. Sliwkowski, and H. M. Stern. 2008. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68: 5878-5887.